Key result
Combining bisoprolol with trimetazidine significantly improved respiratory symptoms, limitation of motion, disease impacts, and SGRQ total scores compared to standard therapy (P<0.05).
Why the study?
Does bisoprolol combined with trimetazidine improve cardiac function and quality of life in heart failure patients with concomitant COPD?
RCT (n=120)
Randomly divided
Does bisoprolol combined with trimetazidine improve cardiac function and quality of life in heart failure patients with concomitant COPD?
p-value: p=<0.05
Combining bisoprolol with trimetazidine improves cardiac function and respiratory symptoms in patients with heart failure and concomitant COPD.
OBJECTIVE: To evaluate the effects of bisoprolol combined with trimetazidine on the treatment of heart failure patients having concomitant chronic obstructive pulmonary disease (COPD); in comparison with control group treated with standard therapy only. METHODS: A total of 120 heart failure patients having concomitant COPD were selected and randomly divided into a control group and a treatment group according to different treatment methods (n=60). The control group was given continuous low flow oxygen inhalation and inotropic agents, and their cardiac stress was also reduced. The treatment group was treated with bisoprolol fumarate and trimetazidine in addition to treatment for COPD. For all patients, blood gas analysis and parameters reflecting cardiac function were measured respectively before and after treatment. The respiratory symptoms (cough, sputum, polypnea, gasp, dyspnea), limitation of motion (daily life, household duties, entertainment, sports), disease impacts (social contact, emotion, anxiety) and St. George's Respiratory Questionnaire (SGRQ) total scores were observed using SGRQ. RESULTS: ) of the treatment group after treatment were significantly different from those before treatment. After treatment, peak E, E/A and IVEF were increased by 41%, 44% and 16% respectively, but peak A, LVPWT/mm and IVST/mm were significantly reduced. The differences in the respiratory symptoms, limitation of motion, disease impacts and SGRQ total scores were statistically significant compared with those before treatment (P<0.05) and those of the control group (P<0.05). CONCLUSION: Combining bisoprolol with trimetazidine in the treatment of heart failure complicating COPD can effectively improve blood gas indices, left ventricular systolic and diastolic functions and the quality of life, thereby alleviating clinical symptoms.
No takes yet. Share an insight, caveat, or question.
Ke et al. (2016) conducted an RCT in Heart failure with concomitant chronic obstructive pulmonary disease (COPD) (n=120). Bisoprolol and trimetazidine vs. Standard therapy (continuous low flow oxygen inhalation, inotropic agents, and cardiac stress reduction) was evaluated on Respiratory symptoms, limitation of motion, disease impacts and SGRQ total scores (p=<0.05). Combining bisoprolol with trimetazidine significantly improved respiratory symptoms, limitation of motion, disease impacts, and SGRQ total scores compared to standard therapy (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: